Facioscapulohumeral dystrophy

Physical Therapy

Volumn 88, Issue 1, 2008, Pages 105-113

  Pandya, Shree ^a   King, Wendy M ^b   Tawil, Rabi ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENETIC DISORDER; HUMAN; MUSCLE ATROPHY; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; PATHOGENESIS; REVIEW;

HUMANS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL;

EID: 37549005500     PISSN: 00319023     EISSN: None     Source Type: Journal    
DOI: 10.2522/ptj.20070104     Document Type: Review

References (65)

1. Emery AEH. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord. 1991;1:19-29.
2. Wijmenga C, Frants RR, Brouwer OF, et al. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet. 1990;336:651-653.
3. Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral dystrophy. Nat Genet. 1992;2:26-30.
4. van der Maarel S, Frants R. The D4Z4 repeat mediated pathogenesis of facioscapulohumeral muscular dystrophy. Am J Hum Genet. 2005;76:375-386.
5. Bakker E, Van der Weiden MJ, Voorhoeve E, et al. Diagnostic, predictive and prenatal testing for facioscapulohumeral dystrophy: diagnostic approach for sporadic and familial cases. J Med Genet. 1996;33:29-35.
6. Upadhyaya M, Maynard J, Rogers MT, et al. Improved molecular diagnosis of facioscapulohumeral muscular dystrophy: validation of the differential double digestion for FSHD. J Med Genet. 1997;34:476-479.
7. Orrell RW, Tawil R, Forrester J, et al. Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology. 1999;52:1822-1826.
8. Upadhyaya M, MacDonald M, Ravine D. Molecular prenatal diagnosis in 12 facioscapulohumeral muscular dystrophy (FSHD) families. Prenat Diagn. 1999;19:959-965.
9. Upadhyaya M, Cooper DN. Molecular diagnosis of facioscapulohumeral muscular dystrophy. Expert Rev Mol Diagn. 2002;2:160-171.
10. Thomas NS, Wiseman K, Spurlock G, et al. A large patient study confirming that facioscapulohumeral muscular dystrophy (FSHD) disease expression is almost exclusively associated with an FSHD locus located on a 4qA-defined 4qter subtelomere. J Med Genet. 2007;44:215-218.
11. Rose MR, Tawil R. Drug treatment for facioscapulohumeral muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD002276.
12. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2006;34:1-15.
13. Kissel JT. Facioscapulohumeral dystrophy. Semin Neurol. 1999;19:35-43.
14. Fitzsimons RB. Facioscapulohumeral muscular dystrophy. Curr Opin Neurol. 1999;12:501-511.
15. Rogers MT. Facioscapulohumeral muscular dystrophy: historical background and literature review. In: Upadhyaya M, Cooper DN, eds. Facioscapulohumeral Muscular Dystrophy. New York, NY: Bios Scientific Publishers; 2004:17-40.
16. Tyler FH, Stephens FE. Studies in disorders of muscle, II: clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family. Ann Intern Med. 1950;32:640-660.
17. Padberg GW. Facioscapulohumeral Disease [thesis]. Leiden, the Netherlands: Leiden University; 1982.
18. Padberg GW, Lunt PW, Kochm M, et al. Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 1991;1:231-234.
19. Trevisan CP, Pastorello E, Armani M, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur Neurol. 2006;56:1-5.
20. Galetta F, Franzoni F, Sposito R. Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2005;15:403-408.
21. Genetics home reference. U.S. National Library of Medicine. Available at: http://ghr.nlm.nih.gov/ghr/glossary/Glossary/show/a. Accessed September 28, 2007.
22. Lemmers RJL, de Kievit P, van Geel M, et al. Complete allele information in the diagnosis of facioscapulohumeral dystrophy by triple DNA analysis. Ann Neurol. 2001;50:816-819.
23. Zatz M, Marie SK, Passos-Bueno MR, et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet. 1995;56:99-105.
24. van der Maarel SM, Deidda G, Lemmers RJ, et al. De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10. Am J Hum Genet. 2000;66:26-35.
25. Lunt PW, Jardine PE, Koch MC, et al. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet. 1995;4:951-958.
26. van der Maarel SM, Frants RR, Padberg GW. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 2007;1772:186-194.
27. Padberg GW, Frants RR, Brouwer OF, et al. Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve. 1995;2:S81-S84.
28. Flanigan KM, Coffeena CM, Sexton L, et al. Genetic characterization of a large, historically significant Utah kindred with FSHD. Neuromuscul Disord. 2001;11:525-529.
29. Padberg GW. Facioscapulohumeral muscular dystrophy: a clinician's experience. In: Upadhyaya M, Cooper DN, eds. Facioscapulohumeral Muscular Dystrophy. New York, NY: Bios Scientific Publishers; 2004:41-54.
30. Bushby KMD, Pollitt C, Johnson MA, et al. Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy: four illustrative case reports. Neuromuscul Disord. 1998;8:574-579.
31. van der Kooi AJ, Visser MC, Rosenberg N, et al. Extension of the clinical range of facioscapulohumeral dystrophy: report of six cases. J Neurol Neurosurg Psychiatry. 2000;69:114-116.
32. Felice KJ, Moore SA. Unusual clinical presentations in patients harboring the facioscapulohumeral dystrophy 4q35 deletion. Muscle Nerve. 2001;24:352-356.
33. Wohlgemuth M, de Swart BJM, Kalf JG, et al. Dysphagia in facioscapulohumeral muscular dystrophy. Neurology. 2006;66:1926-1928.
34. Awerbuch GI, Nigro MA, Wishnow R. Beevor's sign and facioscapulohumeral dystrophy. Arch Neurol. 1990;47:1208-1209.
35. Shahrizaila N, Wills AJ. Significance of Beevor's sign in facioscapulohumeral dystrophy and other neuromuscular diseases. J Neurol Neurosurg Psychiatry. 2005;76:869-870.
36. The FSH-DY Group. A prospective quantitative study of the natural history of facioscapulohumeral muscular dystrophy: implications for therapeutic trials. Neurology. 1997;48:38-46.
37. Olsen DB, Gideon P, Jeppesen TD, Vissing J. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. J Neurol. 2006;253:1437-1441.
38. Johnson EW, Braddon R. Over-work weakness in facioscapulohumeral muscular dystrophy. Arch Phys Med Rehabil. 1971;52:333-335.
39. Brouwer OF, Padberg GW, Van Der Ploeg RJO, et al. The influence of handedness on the distribution of muscular weakness of the arm in facioscapulohumeral muscular dystrophy. Brain. 1992;115:1587-1598.
40. Tawil R, McDermott MP, Mendell JR, et al. FSHD: design of natural history study and results of baseline testing. Neurology. 1994;44:442-446.
41. Wohlgemuth M, van der Kooi EL, van Kasteren RG, et al. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology. 2004;63:176-178.
42. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy: a general association with genetic and therapeutic implications. Brain. 1987;110:631-648.
43. Padberg GW, Brouwer OF, de Keizer RJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve. 1995;2:S73-S80.
44. Urtizberea JA. Results of a French survey of individuals with FSHD. FSH Watch (Publication of FSH Society USA). 1997;summer:37-40.
45. Koetsier CP. Pain related to FSH dystrophy: an underestimated problem? Results of an inquiry in the Netherlands, Baarn VSN. FSH Watch (Publication of FSH Society USA). 1997;summer:23-24.
46. Kalkman JS, Schillings ML, van der Werf SP, et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry. 2005;76:1406-1409.
47. Brooke MH. A Clinician's View of Neuromuscular Diseases. Baltimore, Md: Williams & Wilkins; 1977.
48. Carroll JE, Brooke MH. Infantile facioscapulohumeral dystrophy. In: Serratrice G, Roux H, eds. Peroneal Atrophies and Related Disorders. New York, NY: Masson Publishing USA; 1979:305-319.
49. Brouwer OF, Padberg GW, Wijmenga C, et al. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol. 1994;51:387-394.
50. Klinge L, Eagle M, Haggerty ID, et al. Severe phenotype in facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2006;16:553-558.
51. Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-associated facioscapulohumeral muscular dystrophy. Neurology. 1998;50:1791-1794.
52. Barnett ND, Mander M, Peacock JC, et al. Winging of the scapula: the underlying biomechanics and an orthotic solution. Proc Inst Mech Eng (H). 1995;209:215-223.
53. Mummery CJ, Copeland SA, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev. 2003;(3):CD003278.
54. Facts About Facioscapulohumeral Muscular Dystrophy. Tucson, Ariz: Muscular Dystrophy Association; 2005.
55. van der Kooi EL, Lindeman E, Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev. 2005;(1):CD003907.
56. Lindeman E, Leffers P, Spaans F, et al. Strength training in patients with myotonic dystrophy and hereditary sensory motor neuropathy: a randomized controlled trial. Arch Phys Med Rehabil. 1995:76;612-620.
57. van der Kooi EL, Vogels OJM, van Asseldonk RJGP, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology. 2004;63:702-708.
58. Olsen DB, Orngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral dystrophy. Neurology. 2005;64:1064-1066.
59. Phillips BA, Mastaglia FL. Exercise therapy in patients with myopathy. Curr Opin Neurol. 2000;13:547-552.
60. Fowler WM. Consensus conference summary: role of physical activity and exercise training in neuromuscular diseases. Am J Phys Med Rehabil. 2002;81(suppl):S187-S195.
61. Krivickas LS. Exercise in neuromuscular disease. J Clin Neuromusc Dis. 2003;5:29-39.
62. Noonan V, Dean E. Submaximal exercise testing: clinical application and interpretation. Phys Ther. 2000;80:782-807.
63. Kraemer WJ, Adams K, Cafarelli E, et al. American College of Sports Medicine position stand: progression models in resistance training for healthy adults. Med Sci Sports Exerc. 2002;34:364-380.
64. American College of Sports Medicine Position Stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc. 1998;30:975-991.
65. Haskell WL, Lee IM, Pate RR, et al; American College of Sports Medicine; American Heart Association. Physical activity and public health: updated recommendations for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116:1081-1093. Epub 2007 Aug 1.